Toggle Main Menu Toggle Search

Open Access padlockePrints

Tumour associated glycans: A route to boost immunotherapy?

Lookup NU author(s): Dr Emma ScottORCiD, Professor David Elliott, Dr Jennifer Munkley


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© 2020 Elsevier B.V. While the development of immunotherapies for cancer treatment offer significant promise across several cancers, still only a small subset of patients respond to immune based monotherapies. As such, attention has turned to the development of combination therapies. These use conventional cancer treatments such as chemotherapy to sensitise tumours to immunotherapy. Here, we summarise key research, highlighting the exciting potential of tumour associated glycans as therapeutic targets to sensitise tumours to immunotherapy. When cells undergo carcinogenesis they reprogram their glyco-code. Several cancer associated glycans have been identified, and therapies targeting them are under development. Proteins containing carbohydrate binding domains (lectins) are expressed by many immune cell subtypes, and upon glycan binding, transduce immune modulatory signals that regulate the tumour immune microenvironment.

Publication metadata

Author(s): Scott E, Elliott DJ, Munkley J

Publication type: Review

Publication status: Published

Journal: Clinica Chimica Acta

Year: 2020

Volume: 502

Pages: 167-173

Print publication date: 01/03/2020

Online publication date: 20/12/2019

Acceptance date: 17/12/2019

ISSN (print): 0009-8981

ISSN (electronic): 1873-3492

Publisher: Elsevier B.V.


DOI: 10.1016/j.cca.2019.12.015

PubMed id: 31870793